Sarah Sammons
Associate director of the Metastatic Breast Cancer Program and senior physician at Dana-Farber Cancer Institute, and an assistant professor of medicine at Harvard Medical School; discusses clinical trial data and rationale for pumitamig in triple-negative breast cancer.
Best podcasts with Sarah Sammons
Ranked by the Snipd community
Feb 26, 2026 • 11min
S16 Ep14: Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD
Sarah Sammons, MD, an associate director at Dana-Farber and Harvard faculty, outlines pumitamig, a bispecific PD-L1/VEGF-A antibody. She explains the drug’s mechanism and rationale. She reviews phase 2 trial design, strong response rates, safety signals, and plans for a phase 3 registrational study. She also places pumitamig among emerging immunotherapy and ADC strategies for triple-negative breast cancer.
